Thermo Fisher Scientific said Q4 2024 revenue was $11.40 billion, up 5% from $10.89 billion in the prior-year period. GAAP operating income was $2.02 billion and GAAP operating margin was 17.7%.

1. 01

   Thermo Fisher Scientific said Q4 2024 revenue was $11.40 billion, up 5% from $10.89 billion in the prior-year period. GAAP operating income was $2.02 billion and GAAP operating margin was 17.7%.

2. 02

   The company said 2024 revenue was $42.88 billion, flat versus 2023 revenue of $42.86 billion, and adjusted operating income was $9.71 billion compared with 2023 adjusted operating income of $9.81 billion. Adjusted operating margin was 22.6% versus 22.9% in 2023.

3. 03

   Thermo Fisher Scientific said full-year 2024 GAAP diluted EPS was $16.53, up 7% from $15.45 in 2023. Adjusted EPS for the same period was $21.86, up 1% from $21.55 in 2023.

4. 04

   The company disclosed that net cash provided by operating activities for 2024 was $8,667 million and free cash flow was $7,324 million. It completed the acquisition of Olink in the year and returned $4.6 billion to shareholders through stock buybacks and dividends.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.